VIR Biotechnology.
biotech company
- Reports this week
- 2
- Active events
- 2
- Connections
- 46
What's happening
Active this week
One to three months ago
Gone quiet
No new reports in 90+ days-
Janet Napolitano and Renaissance Technologies filed reports regarding buying and selling shares of Vir Biotechnology stock with the SEC.Some support1 report
-
Brii Biosciences and VIR Biotechnology engaged regarding chronic hepatitis B virus therapies, including an arbitration over manufacturing technology transfer.Some support3 reports
-
The ECLIPSE program is the registrational program for Vir Biotechnology.Some support1 report
-
The ECLIPSE program is the registrational program for Vir Biotechnology, and the trial supports global marketing in Europe.Some support1 report
-
Dr. Alan J. Korman was appointed to Invenra's Scientific Advisory Board, where Roland Green serves as CEO.Some support1 report
-
Sanofi and VIR Biotechnology signed an exclusive global license agreement for the PRO-XTEN platform.Some support1 report1 development inside
-
VIR Biotechnology is developing TCEs targeting EGFR for solid tumors, specifically testing treatments for non-small cell lung cancer and colorectal cancer.Some support1 report
-
Vir Biotechnology shares lost 30.4% on August 7, 2025, against a gain in the S&P 500.Some support1 report
-
CEO of VIR Biotechnology participated in a conference chat hosted by Morgan Stanley on August 26, 2025.Some support1 report
-
Bank of America upgraded VIR Biotechnology's stock rating, citing its potential in liver therapy.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around VIR Biotechnology this week
News at the entities that move VIR Biotechnology most-
SEC StructuralMangoceuticals, a Nasdaq-listed company, filed an offering statement with the SEC and partnered with T7X for tokenized stock issuance.Moves VIR Biotechnology
-
Royal Bank of Canada TransactionalMagnolia, State of Wyoming, and Royal Bank of Canada adjusted their investment holdings in Natural Resource Partners LP shares.Moves VIR Biotechnology
-
Amundi TransactionalAlabama retirement systems lowered their position while Amundi increased its stake and Jefferies issued a hold rating.Moves VIR Biotechnology
-
Morgan Stanley TransactionalMetro Bank invited bidders to contact Morgan Stanley on November 12, 2026.Moves VIR Biotechnology
-
TD Cowen OperationalTD Cowen is based in Toronto.Moves VIR Biotechnology
-
Raymond James Financial Mentioned togetherRaymond James Financial, JPMorgan Chase, and Bank of America Corp DE issued rating changes and coverage updates on News Corporation.Moves VIR Biotechnology
Connections
The 12 strongest of 46, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
SEC Structural
VIR Biotechnology is subject to mandatory regulatory oversight and filing requirements by the SEC.
-
Astellas Pharma Operational
Astellas Pharma and VIR Biotechnology are collaborating on the joint development of a PSMA-targeted T-cell engager.
-
Royal Bank of Canada Transactional
Royal Bank of Canada increased its investment position in VIR Biotechnology.
-
Amundi Transactional
Amundi increased its investment holdings in VIR Biotechnology.
-
Nasdaq Structural
VIR Biotechnology's shares are listed and traded on the Nasdaq stock exchange.
-
Morgan Stanley Transactional
Morgan Stanley issues and updates price targets and ratings for VIR Biotechnology.
-
TD Cowen Operational
TD Cowen provides investment ratings and coverage for VIR Biotechnology, which participates in TD Cowen's industry summits.
-
Janet Napolitano Transactional
Janet Napolitano sold shares of VIR Biotechnology.
Show all 12 connections
-
Renaissance Technologies Transactional
Renaissance Technologies increased its investment holdings in VIR Biotechnology shares.
-
Raymond James Financial Mentioned together
Raymond James Financial provided a strong-buy rating on VIR Biotechnology.
-
Needham Mentioned together
Needham provided a buy rating and boosted the target price for VIR Biotechnology.
-
Netherlands Shared context
VIR Biotechnology conducts clinical data presentations within the Netherlands.
History
Events by the month they beganNovember 2026
1 eventOctober 2026
2 eventsAugust 2026
1 eventShow 2 earlier months
June 2026
8 events- The ECLIPSE program is the registrational program for Vir Biotechnology.
- The ECLIPSE program is the registrational program for Vir Biotechnology, and the trial supports global marketing in Europe.
- Dr. Alan J. Korman was appointed to Invenra's Scientific Advisory Board, where Roland Green serves as CEO.
- Sanofi and VIR Biotechnology signed an exclusive global license agreement for the PRO-XTEN platform.
- VIR Biotechnology is developing TCEs targeting EGFR for solid tumors, specifically testing treatments for non-small cell lung cancer and colorectal cancer.
- Vir Biotechnology shares lost 30.4% on August 7, 2025, against a gain in the S&P 500.
- CEO of VIR Biotechnology participated in a conference chat hosted by Morgan Stanley on August 26, 2025.
- Bank of America upgraded VIR Biotechnology's stock rating, citing its potential in liver therapy.